Cargando…

Utilization of risk assessment tools in management of PAH: A PAH provider survey

Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use is low. We conducted a survey to assess potential reasons fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahay, Sandeep, Balasubramanian, Vijay, Memon, Humna, Poms, Abby, Bossone, Eduardo, Highland, Kristine, Kay, Dana, Levine, Deborah J, Mullin, Christopher J, Melendres‐Groves, Lana, Mathai, Stephen C, Soto, Francisco J, Shlobin, Oksana, Elwing, Jean M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063963/
https://www.ncbi.nlm.nih.gov/pubmed/35514787
http://dx.doi.org/10.1002/pul2.12057
_version_ 1784699265795227648
author Sahay, Sandeep
Balasubramanian, Vijay
Memon, Humna
Poms, Abby
Bossone, Eduardo
Highland, Kristine
Kay, Dana
Levine, Deborah J
Mullin, Christopher J
Melendres‐Groves, Lana
Mathai, Stephen C
Soto, Francisco J
Shlobin, Oksana
Elwing, Jean M
author_facet Sahay, Sandeep
Balasubramanian, Vijay
Memon, Humna
Poms, Abby
Bossone, Eduardo
Highland, Kristine
Kay, Dana
Levine, Deborah J
Mullin, Christopher J
Melendres‐Groves, Lana
Mathai, Stephen C
Soto, Francisco J
Shlobin, Oksana
Elwing, Jean M
author_sort Sahay, Sandeep
collection PubMed
description Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use is low. We conducted a survey to assess potential reasons for under‐utilization. We conducted a survey‐based study of global PAH disease specialists with a goal of assessing risk assessment utilization and identifying modifiable barriers to use. The survey was designed by the American College of Chest Physicians’ Pulmonary Vascular Diseases (PVD) NetWork. Respondents were global members of the PVD NetWork and Pulmonary Hypertension Association. Survey invitations were sent electronically to all members. Participation was anonymous and no provider or patient level data was collected. Participants from four countries responded with the majority (84%) being from the United States. Our survey found suboptimal use of any risk stratification tool with 71/112 (63%) reporting use. A total of 85% of the respondents had more than 5 years of experience in managing PAH. REVEAL 2.0 and European Society of Cardiology/European Respiratory Society risk tools were the most commonly used. A total of 44 (65%) surveyed felt that use of risk tools led to change in PAH therapies. Only 6 (9%) felt they prompted additional testing or changed the frequency of follow‐up. A total of 5 (7%) reported they prompted goals of care/palliative care discussions and 2 (3%) that they triggered lung transplant referral. The vast majority indicated that incorporation of risk tools into electronic medical records (EMR) would improve utilization. PAH risk assessment tools remain under‐utilized. Most respondents were experienced PAH clinicians. More than one‐third were not routinely using risk tools. Most felt that risk tools led to PAH therapy changes but few reported impacts on other aspects of care. The most commonly identified barriers to use were time constraints and lack of integration with EMR.
format Online
Article
Text
id pubmed-9063963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90639632022-05-04 Utilization of risk assessment tools in management of PAH: A PAH provider survey Sahay, Sandeep Balasubramanian, Vijay Memon, Humna Poms, Abby Bossone, Eduardo Highland, Kristine Kay, Dana Levine, Deborah J Mullin, Christopher J Melendres‐Groves, Lana Mathai, Stephen C Soto, Francisco J Shlobin, Oksana Elwing, Jean M Pulm Circ Research Articles Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use is low. We conducted a survey to assess potential reasons for under‐utilization. We conducted a survey‐based study of global PAH disease specialists with a goal of assessing risk assessment utilization and identifying modifiable barriers to use. The survey was designed by the American College of Chest Physicians’ Pulmonary Vascular Diseases (PVD) NetWork. Respondents were global members of the PVD NetWork and Pulmonary Hypertension Association. Survey invitations were sent electronically to all members. Participation was anonymous and no provider or patient level data was collected. Participants from four countries responded with the majority (84%) being from the United States. Our survey found suboptimal use of any risk stratification tool with 71/112 (63%) reporting use. A total of 85% of the respondents had more than 5 years of experience in managing PAH. REVEAL 2.0 and European Society of Cardiology/European Respiratory Society risk tools were the most commonly used. A total of 44 (65%) surveyed felt that use of risk tools led to change in PAH therapies. Only 6 (9%) felt they prompted additional testing or changed the frequency of follow‐up. A total of 5 (7%) reported they prompted goals of care/palliative care discussions and 2 (3%) that they triggered lung transplant referral. The vast majority indicated that incorporation of risk tools into electronic medical records (EMR) would improve utilization. PAH risk assessment tools remain under‐utilized. Most respondents were experienced PAH clinicians. More than one‐third were not routinely using risk tools. Most felt that risk tools led to PAH therapy changes but few reported impacts on other aspects of care. The most commonly identified barriers to use were time constraints and lack of integration with EMR. John Wiley and Sons Inc. 2022-04-08 /pmc/articles/PMC9063963/ /pubmed/35514787 http://dx.doi.org/10.1002/pul2.12057 Text en © 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Sahay, Sandeep
Balasubramanian, Vijay
Memon, Humna
Poms, Abby
Bossone, Eduardo
Highland, Kristine
Kay, Dana
Levine, Deborah J
Mullin, Christopher J
Melendres‐Groves, Lana
Mathai, Stephen C
Soto, Francisco J
Shlobin, Oksana
Elwing, Jean M
Utilization of risk assessment tools in management of PAH: A PAH provider survey
title Utilization of risk assessment tools in management of PAH: A PAH provider survey
title_full Utilization of risk assessment tools in management of PAH: A PAH provider survey
title_fullStr Utilization of risk assessment tools in management of PAH: A PAH provider survey
title_full_unstemmed Utilization of risk assessment tools in management of PAH: A PAH provider survey
title_short Utilization of risk assessment tools in management of PAH: A PAH provider survey
title_sort utilization of risk assessment tools in management of pah: a pah provider survey
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063963/
https://www.ncbi.nlm.nih.gov/pubmed/35514787
http://dx.doi.org/10.1002/pul2.12057
work_keys_str_mv AT sahaysandeep utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT balasubramanianvijay utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT memonhumna utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT pomsabby utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT bossoneeduardo utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT highlandkristine utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT kaydana utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT levinedeborahj utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT mullinchristopherj utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT melendresgroveslana utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT mathaistephenc utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT sotofranciscoj utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT shlobinoksana utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey
AT elwingjeanm utilizationofriskassessmenttoolsinmanagementofpahapahprovidersurvey